The goal of this activity is for learners to be better able to analyze and apply the latest clinical trial data investigating selective estrogen receptor degraders (SERDs) for treatment of ER-positive/HER2-negative metastatic breast cancer.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1002163
- Start Date: 2025-01-13 06:00:00
- End Date: 2025-01-13 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Lilly (Any division) - Amount: 94080.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest